Genotoxicity of iron chelators in L5178Y mouse lymphoma cells

Environmental and Molecular Mutagenesis

Volumn 38, Issue 4, 2001, Pages 347-356

  Whittaker, Paul ^a   Seifried, Harold E ^b   San, Richard H C ^c   Clarke, Jane J ^c   Dunkel, Virginia C ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c BioReliance   (United States)

Author keywords

Iron chelotors; Iron toxicity; Mouse lymphoma assay; Mutagenicity; Thalassemia

Indexed keywords

DEFEROXAMINE; DEFEROXAMINE MESYLATE; EDETATE SODIUM; FERROZINE; IRON CHELATING AGENT; PHYTIC ACID;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENOTOXICITY; LYMPHOMA; MOUSE; MUTAGENICITY; NONHUMAN; THALASSEMIA; TOXICITY TESTING;

ANIMALS; EDETIC ACID; IRON CHELATING AGENTS; LYMPHOMA; MICE; MUTAGENICITY TESTS; PHENANTHROLINES; PYRIDONES; RAZOXANE; TUMOR CELLS, CULTURED;

ANIMALIA;

EID: 0035688350     PISSN: 08936692     EISSN: None     Source Type: Journal    
DOI: 10.1002/em.10033     Document Type: Article

References (32)

1. Development of iron-chelating agents for clinical use
2. Laboratory procedure for assessing specific locus mutations at the TK locus in cultured L5178Y TK+/- mouse lymphoma cells
3. Evidence for chemically-induced structural gene mutations at the thymidine kinase locus in cultured L5178Y mouse lymphoma cells
4. Validation and characterization of the L5178Y/TK+/- mouse lymphoma mutagen assay system
5. A comparison of bathophenanthrolinedisulfonic acid and ferrozine as chelators of iron(II) in reduction reactions
6. First human studies with a high-molecular weight iron chelator
7. Genotoxicity of iron compounds in Sallmonella typhimurium and L5178Y mouse lymphoma cells
8. Studies of the culture of leukemic cells in vitro
9. An evaluation of the potential of HBED as an orally effective iron-chelating drug
10. Results from a phase I clinical trial of HBED
11. Phytic acid: A natural antioxidant
12. Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers
13. Iron chelators for thalassaemia
14. Lipid peroxidation in iron-overloaded spleens
15. The biochemistry of deferoxamine and its relation to iron metabolism
16. Regulating the fate of mRNA; the control of cellular iron metabolism
17. The study of iron mobilisation from transferrin using alpha-ketohydroxy heteroaromatic chelators
18. Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminum chelating drugs
19. Transfusional iron overload and chelation therapy with deferoxamine and defefiprone (L1)
20. The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity
21. New multidentate ligands. VI. Chelating tendencies of N,N′-di(2-hydroxybenzyl)ethylenediamine-N,N′-diacetic acid
22. Stabilities of the iron(III) chelates of 1,2-dimethyl-3-hydroxy-4-pyridinone and related ligands
23. Iron-chelating therapy and the treatment of thalassemia
24. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
25. Evaluation of new iron chelators for clinical use
26. The development of iron chelating drugs
27. Comparison of the subacute toxicity and efficacy of orally active 3-hydroxypyridin-4-one iron chelators
28. The therapeutic potential of iron chelators
29. Moderate elevation of body iron level and increased risk of cancer occurrence and death
30. Modulation of transferrin receptor expression by dexrazoxane (ICRF-187) via activation of iron regulatory protein
31. Dexrazoxane (ICRF-187)
32. Histopathological evaluation of liver, pancreas, spleen, and heart from iron-overloaded Sprague-Dawley rats